Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Mercer

Showing results (311-320 of 321) with videos related to

Pageof 33
Sort By:
Database : the Journal of Biological Databases and Curation|March 7, 2023
Chemical identification and indexing in full-text articles: an overview of the NLM-Chem track at BioCreative VIIRobert Leaman, Rezarta Islamaj, Virginia Adams, et al.
Bioorganic & Medicinal Chemistry Letters|October 23, 2020
Azepino-indazoles as calcitonin gene-related peptide (CGRP) receptor antagonistsStephen E Mercer, Prasad V Chaturvedula, Charles M Conway, et al.
Current Oncology (Toronto, Ont.)|December 13, 2021
Building a National Reassessment Process for Oncology Drugs: Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration through a Simulated Reassessment ExerciseWei Fang Dai, Erica Craig, Brent Fraser, et al.
Iscience|November 14, 2022
Enhanced virulence and waning vaccine-elicited antibodies account for breakthrough infections caused by SARS-CoV-2 delta and beyondHyung-Joon Kwon, Martina Kosikova, Weichun Tang, et al.
Current Oncology (Toronto, Ont.)|May 15, 2023
Development of a Multi-Criteria Decision Analysis Rating Tool to Prioritize Real-World Evidence Questions for the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) CollaborationAmbica Parmar, Wei Fang Dai, Francois Dionne, et al.
Current Oncology (Toronto, Ont.)|October 22, 2021
Considerations for Developing a Reassessment Process: Report from the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration's Reassessment and Uptake Working GroupWei Fang Dai, Vanessa Arciero, Erica Craig, et al.
Current Oncology (Toronto, Ont.)|March 24, 2022
Mapping Canadian Data Assets to Generate Real-World Evidence: Lessons Learned from Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration's RWE Data Working GroupWei Fang Dai, Claire de Oliveira, Scott Blommaert, et al.
International Journal of Cancer|April 23, 2025
Real-world comparative effectiveness and safety of Pertuzumab in patients with HER2+ metastatic breast cancer: A pan-Canadian population-based cohort studyCaroline E Muñoz, Wei Fang Dai, Winson Y Cheung, et al.
Molecular Therapy. Nucleic Acids|September 12, 2022
Identification and characterization of a MAPT-targeting locked nucleic acid antisense oligonucleotide therapeutic for tauopathiesAmy Easton, Marianne L Jensen, Congwei Wang, et al.
Nature Communications|May 25, 2017
A tetraoxane-based antimalarial drug candidate that overcomes PfK13-C580Y dependent artemisinin resistancePaul M O'Neill, Richard K Amewu, Susan A Charman, et al.
Pageof 33

Showing results (311-320 of 321) with videos related to

Sort By:
Pageof 33
Database : the Journal of Biological Databases and Curation|March 7, 2023
Chemical identification and indexing in full-text articles: an overview of the NLM-Chem track at BioCreative VIIRobert Leaman, Rezarta Islamaj, Virginia Adams, et al.
Bioorganic & Medicinal Chemistry Letters|October 23, 2020
Azepino-indazoles as calcitonin gene-related peptide (CGRP) receptor antagonistsStephen E Mercer, Prasad V Chaturvedula, Charles M Conway, et al.
Current Oncology (Toronto, Ont.)|December 13, 2021
Building a National Reassessment Process for Oncology Drugs: Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration through a Simulated Reassessment ExerciseWei Fang Dai, Erica Craig, Brent Fraser, et al.
Iscience|November 14, 2022
Enhanced virulence and waning vaccine-elicited antibodies account for breakthrough infections caused by SARS-CoV-2 delta and beyondHyung-Joon Kwon, Martina Kosikova, Weichun Tang, et al.
Current Oncology (Toronto, Ont.)|May 15, 2023
Development of a Multi-Criteria Decision Analysis Rating Tool to Prioritize Real-World Evidence Questions for the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) CollaborationAmbica Parmar, Wei Fang Dai, Francois Dionne, et al.
Current Oncology (Toronto, Ont.)|October 22, 2021
Considerations for Developing a Reassessment Process: Report from the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration's Reassessment and Uptake Working GroupWei Fang Dai, Vanessa Arciero, Erica Craig, et al.
Current Oncology (Toronto, Ont.)|March 24, 2022
Mapping Canadian Data Assets to Generate Real-World Evidence: Lessons Learned from Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration's RWE Data Working GroupWei Fang Dai, Claire de Oliveira, Scott Blommaert, et al.
International Journal of Cancer|April 23, 2025
Real-world comparative effectiveness and safety of Pertuzumab in patients with HER2+ metastatic breast cancer: A pan-Canadian population-based cohort studyCaroline E Muñoz, Wei Fang Dai, Winson Y Cheung, et al.
Molecular Therapy. Nucleic Acids|September 12, 2022
Identification and characterization of a MAPT-targeting locked nucleic acid antisense oligonucleotide therapeutic for tauopathiesAmy Easton, Marianne L Jensen, Congwei Wang, et al.
Nature Communications|May 25, 2017
A tetraoxane-based antimalarial drug candidate that overcomes PfK13-C580Y dependent artemisinin resistancePaul M O'Neill, Richard K Amewu, Susan A Charman, et al.
Pageof 33